medigraphic.com

2004, Número s2

<< Anterior Siguiente >>

Arch Cardiol Mex 2004; 74 (s2)


Paradigmas cambiantes en la aterotrombosis:Inflamación y neovascularización en la progresión, ruptura y regresión de la placa

Fuster V, Corti R, Moreno PR

Idioma: Ingles.
Referencias bibliográficas: 55
Paginas: 156-163
Archivo PDF: 121.33 Kb.


RESUMEN

La aterotrombosis coronaria sigue siendo la causa más frecuente de enfermedad isquémica. La ruptura/erosión de la placa con trombosis superpuesta es la causa principal de los síndromes coronarios agudos y de la muerte súbita cardíaca. Los nuevos hallazgos han introducido conceptos que podrían impactar de manera muy importante el tratamiento de esta patología. Discutiremos los mecanismos que desencadenan en el desarrollo de la aterotrombosis y en aquellos responsables del síndrome coronario agudo. En particular, se revisará la participación de la remodelación arterial así como el papel de la media/adventicia y de los tejidos en la aterotrombosis. Finalmente, se discuten los mecanismos actuales participantes en la regresión de la placa.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Fuster V, Fayad ZA, Badimon JJ: Acute coronary syndromes: biology. Lancet 1999; 353(Suppl. 2): SII5-9.

  2. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104(3): 365-72.

  3. Lusis AJ: Atherosclerosis. Nature 2000; 407(6801): 233-41.

  4. Corti R, Fuster V, Badimon JJ, Hutter R, Fayad ZA: New understanding of atherosclerosis (clinically and experimentally) with evolving MRI technology in vivo. Ann N Y Acad Sci 2001; 947: 181-95; discussion 195-8.

  5. Corti R, Badimon JJ: Biologic aspects of vulnerable plaque. Curr Opin Cardiol 2002; 17(6): 616-25.

  6. Gibbons G, Dzau VJ: The Emerging Concept of Vascular Remodeling. N Engl J Med 1994; 330: 1431-1438.

  7. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-5.

  8. Pasterkamp G, Schoneveld AH, van der Wal AC, Haudenschild CC, Clarijs RJ, Becker AE, Hillen B, Borst C: Relation of arterial geometry to luminal narrowing and histologic markers for plaque vulnerability: the remodeling paradox. J Am Coll Cardiol 1998; 32(3): 655-62.

  9. Schoenhagen P, Ziada KM, Kapadia SR, et al: Extent and Direction of Arterial Remodeling in Stable Versus Unstable Coronary Syndromes: An Intravascular Ultrasound Study Circulation; 2000; 101: 598-603.

  10. Tronc F, Mallat Z, Lehoux S, Wassef M, Esposito B, Tedgui A: Role of matrix metalloproteinases in blood flow-induced arterial enlargement: interaction with NO. Arterioscler Thromb Vasc Biol 2000; 20(12): E120-6.

  11. Moreno PR, Purushothaman RK, Fuster V, O’Connor WN: Increased incidence of internal elastic lamina rupture and intimal changes in complex atherosclerotic lesions: Understanding the remodeling paradox and plaque disruption. J Am Coll Cardiol 2002; 39(5 (Suppl. A)): 247A (Abs.).

  12. Burke AP, Kolodgie FD, Farb A, Weber D, Virmani R: Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation 2002; 105(3): 297-303.

  13. Herrmann J, Lerman LO, Rodriguez-Porcel M, et al: Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc Res 2001; 51: 762-6.

  14. Nakata Y, Shionoya S: Vascular lesions due to obstruction of the vasa vasorum. Nature 1966; 212: 1258-1259.

  15. Barger AC, Beeuwkes IIIR, Lainley LL, et al: Hypothesis: vasa vasorum and neovascularization of human coronary arteries. New Engl J Med 1984; 310: 175-177.

  16. Martin JF, Booth RFG, Moncada S: Arterial wall hypoxia following thrombosis of the vasa vasorum is an initial lesion in atherosclerosis. Eur J Clin Invest 1991; 21: 355-359.

  17. Stefanadis CI, Karayannacos PE, Boudouas HK, et al: Medial necrosis and acute alterations in aortic distensibility following removal of the vasa vasorum of canine ascending aorta. Cardiovasc Res 1993; 27: 951-956.

  18. Barker SGE, Talbert A, Cottam S, et al: Martin, Arterial intimal hyperplasia after occlusion of the adventitial vasa vasorum in the pig. Arterioscler Thromb Vasc Biol 1993; 13: 70-77.

  19. Barker SGE, Tilling LC, Miller GC, et al: The adventitia and atherogenesis:removal initiates intimal proliferation in the rabbit which regresses on generation of a “neoadventitia”. Atherosclerosis 1994; 105: 131-144.

  20. De Mayer GRY, Van Put DJM, Kockx MM, et al: Possible mechanisms of collar-induced intimal thickening. Arterioscler Thromb Vasc Biol 1997; 17: 1924-1930.

  21. Moulton KS, Heller E, Konerding MA, et al: Angiogenesis Inhibitors Endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E–deficient mice. Circulation 1999; 99: 1726-1732.

  22. Heistad DD, Marcus M: Role of vasa vasorum in nourishment of the aorta. Blood Vessels 1979; 16: 225-23823.

  23. Kwon HM, Sangiorgi G, Ritman EL, et al: Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998; 101: 1551-6.

  24. Scotland RS, Vallance PJT, Ahluwalia A: Endogenous factors involved in regulation of tone of arterial vasa vasorum: implications for conduit vessel physiology. Cardiovasc Research 2000; 46: 403-411.

  25. Kumamoto M, Nakashima Y, Sueishi K: Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. Hum Pathol 1995; 26: 450-456.

  26. Moreno PR, Purushothaman KR, O’Connor WN, Booth DC, Fuster V, Muller JE: Increased neovascularization in disrupted human atherosclerotic plaques. JACC 2000; 35: 275A. Purushothaman KR, Fuster V, O’Connor WN, Moreno PR.

  27. Neovascularization is the Most Powerful Independent Predictor for Progression to Disruption in High-Risk Atherosclerotic Plaques. JACC 2003; 41(6 Suppl B): 352-353.

  28. Purushothaman KR, Echeverri D, Fuster V, O’Connor WN, Moreno PR: Neovascularization, inflammation and intra-plaque hemorrhage are increased in advanced human atherosclerosis from patients with diabetes mellitus. Circulation 2003; 108: IV-98;459.

  29. Moreno PR, Purushothaman KR, Fuster V, O’Connor WN: Lipid core reduction is associated with decreased neovascularization in fibro-calcific atherosclerosis: implications for plaque regression. Circulation 2002; II-703: 3468.

  30. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, et al: Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002; 106: 2884-2887.

  31. Nissen S: Reversal Trial. American Heart Association Meeting, 2003. http://www.prous.com/aha2003/home.asp

  32. Worthley SG, Helft G, Fuster V, et al: Serial in vivo MRI documents arterial remodeling in experimental atherosclerosis. Circulation 2000; 101(6): 586-9.

  33. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995; 92(3): 657-71.

  34. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, et al: Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12(1): 56-62.

  35. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, et al: Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78(5 Pt 1): 1157-66.

  36. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20(5): 1262-75.

  37. Rauch U, Crandall J, Osende JI, Fallon JT, Chesebro JH, Fuster V, et al: Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2. Am J Cardiol 2000; 86(2): 246-9.

  38. Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, et al: Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001; 38(5): 1307-12.

  39. Corti R, Badimon JJ: Value or desirability of hemorrheological-hemostatic parameter changes as endpoints in blood lipid-regulating trials. Curr Opin Lipidol 2001; 12(6): 629-37.

  40. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, et al: Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107(7): 973-977.

  41. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, et al: Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99(14): 1780-7.

  42. Roque M, Reis ED, Fuster V, Padurean A, Fallon JT, Taubman MB, et al: Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. J Am Coll Cardiol 2000; 36(7): 2303-10.

  43. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, et al: Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95(3): 594-9.

  44. Nemerson Y: Tissue factor and hemostasis. Blood 1988; 71(1): 1-8.

  45. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al: Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96(5): 2311-5.

  46. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, et al: Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96(1): 170-5.

  47. Soejima H, Ogawa H, Yasue H, Kaikita K, Nishiyama K, Misumi K, et al: Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99(22): 2908-13.

  48. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, et al: Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101(8): 841-3.

  49. Corti R, Fuster V, Badimon JJ: Strategy for ensuring a better future for the vessel wall. Eur Heart J Supplements 2002; 4(Suppl. 4): A31-A41.

  50. Mallat Z, Tedgui A: Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 2001; 88(10): 998-1003.

  51. Hutter R, Sauter B, Fallon JT, Fuster V, Badimon JJ: Macrophages and Vascular Stellate Cells in Human Carotid Plaques are Prone to Apoptosis and Tissue Factor Expression. J Am Coll Cardiol 2001; 37(2 (Suppl. A)): 288A.

  52. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345(22): 1583-92.

  53. Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990; 85(4): 1234-41.

  54. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, et al: High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105(12): 1399-402.

  55. Corti R, Osende J, Fallon JT, Fuster V, et al: The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging. J Am Coll Cardiol 2004: 464-473.




2020     |     www.medigraphic.com